This systematic review and meta-analysis evaluated the effectiveness of lorcaserin, a selective serotonin 2C receptor agonist, for weight reduction. Five randomized controlled trials involving over 9,000 patients were included. Lorcaserin administered once or twice daily resulted in statistically significant weight loss of 1.95kg and 2.74kg respectively compared to placebo. Lorcaserin also improved other outcomes like waist circumference and cardiometabolic parameters. The most common adverse effects with lorcaserin were headache, upper respiratory infection, and dizziness. Long term studies are still needed to evaluate lorcaserin's effects on sustained weight loss and cost-effectiveness.